Neoadjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria: An interim analysis of a multi-center, phase 3, randomized, controlled clinical trial.

Shao hua Li,Chong Zhong,Qiang Li,Jingwen Zou,Qiaoxuan Wang,Changzhen Shang,Yuan Cheng,Mingrong Cao,Huakun Huang,Jie Mei,Liang He Lu,Rong-Ce Zhao,Wenping Lin,Yuhua Wen,Zhixing Guo,Yihong Ling,Lie Zheng,Wei Wei,Rong Ping Guo

Neoadjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria: An interim analysis of a multi-center, phase 3, randomized, controlled clinical trial.

2021

Shao hua Li
Chong Zhong
Qiang Li
Jingwen Zou
Qiaoxuan Wang
Changzhen Shang
Yuan Cheng
Mingrong Cao
Huakun Huang
Jie Mei
Liang He Lu
Rong-Ce Zhao
Wenping Lin
Yuhua Wen
Zhixing Guo
Yihong Ling
Lie Zheng
Wei Wei
Rong Ping Guo

4008Background: The efficacy of operation, as the only radical option for resectable BCLC stage A/B hepatocellular carcinoma (HCC) patients beyond Milan criteria, is still unsatisfactory. This stud...

Keywords:

FOLFOX
infusion chemotherapy
Radiology
Medicine
Milan criteria
Hepatocellular carcinoma
Interim analysis
Clinical trial
BCLC Stage

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations